Thursday, January 20, 2011

BIOCON ORAL INSULIN

The company says that the drug failed to meet its primary endpoint of reduction in HbA1C ,because of unusually high placebo effect driven by lifestyle changes.  For a double blind trial, I dont think that should be the case, as patients were blinded to the treatment offered to them.

If this is true, the most important thing to learn here is that lifestyle changes can give as effective results as a drug. Probably a good news for diabetics.